Skip to main content
. 2019 Dec 9;12:401–413. doi: 10.2147/JAA.S227170

Figure 1.

Figure 1

Benralizumab 2-Year Integrated Analysis Study Design.

Abbreviations: NA, not available; Q4W, every 4 weeks; Q8W, every 8 weeks (first three doses Q4W); SC, subcutaneously.